Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Longkanker vroeg opsporen om de overlevingskans (sterk) te verhogen
dec 2019 | Immuuntherapie, Longoncologie